Olav Dalgård

14.0k total citations · 2 hit papers
95 papers, 4.9k citations indexed

About

Olav Dalgård is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Olav Dalgård has authored 95 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Hepatology, 78 papers in Epidemiology and 6 papers in Infectious Diseases. Recurrent topics in Olav Dalgård's work include Hepatitis C virus research (86 papers), Liver Disease Diagnosis and Treatment (59 papers) and Hepatitis B Virus Studies (56 papers). Olav Dalgård is often cited by papers focused on Hepatitis C virus research (86 papers), Liver Disease Diagnosis and Treatment (59 papers) and Hepatitis B Virus Studies (56 papers). Olav Dalgård collaborates with scholars based in Norway, Sweden and Denmark. Olav Dalgård's co-authors include Alessio Aghemo, Massimo Puoti, Heiner Wedemeyer, Jean–Michel Pawlotsky, Francesco Negro, Marina Berenguer, Geoffrey Dusheiko, Kjell Skaug, Kristian Bjøro and Kjell B. Hellum and has published in prestigious journals such as Nature Communications, Gastroenterology and PLoS ONE.

In The Last Decade

Olav Dalgård

87 papers receiving 4.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EASL Recommendations on Treatment of Hepatitis C 2018

2018 1.5k citations Jean–Michel Pawlotsky, Francesco Negro et al. Journal of Hepatology profile →
EASL recommendations on treatment of hepatitis C: Final update of the series☆

2020 707 citations Jean–Michel Pawlotsky, Francesco Negro et al. Journal of Hepatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Olav Dalgård	4.3k	4.1k	723	336	227	95	4.9k
Donald M. Jensen	3.7k 0.9×	3.7k 0.9×	594 0.8×	189 0.6×	386 1.7×	114	4.8k
Stefan Mauss	4.3k 1.0×	4.1k 1.0×	1.8k 2.5×	257 0.8×	167 0.7×	191	5.6k
Evangelista Sagnelli	4.4k 1.0×	4.5k 1.1×	663 0.9×	137 0.4×	141 0.6×	238	5.6k
Vincent Di Martino	4.2k 1.0×	4.1k 1.0×	812 1.1×	157 0.5×	142 0.6×	148	5.7k
Yves Benhamou	7.0k 1.6×	7.0k 1.7×	1.6k 2.3×	163 0.5×	222 1.0×	101	8.2k
Robert H. Hyland	3.2k 0.8×	3.9k 0.9×	1.0k 1.4×	140 0.4×	281 1.2×	119	7.2k
Maureen M. Jonas	6.6k 1.6×	7.2k 1.8×	716 1.0×	238 0.7×	150 0.7×	127	8.2k
Behzad Hajarizadeh	4.0k 1.0×	4.1k 1.0×	741 1.0×	113 0.3×	100 0.4×	172	5.0k
Giovanni Battista Gaeta	2.5k 0.6×	2.7k 0.7×	306 0.4×	200 0.6×	135 0.6×	113	3.4k
Eduardo Lissen	3.6k 0.8×	4.2k 1.0×	730 1.0×	193 0.6×	103 0.5×	30	5.1k

Countries citing papers authored by Olav Dalgård

Since Specialization

Citations

This map shows the geographic impact of Olav Dalgård's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olav Dalgård with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olav Dalgård more than expected).

Fields of papers citing papers by Olav Dalgård

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olav Dalgård. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olav Dalgård. The network helps show where Olav Dalgård may publish in the future.

Co-authorship network of co-authors of Olav Dalgård

This figure shows the co-authorship network connecting the top 25 collaborators of Olav Dalgård. A scholar is included among the top collaborators of Olav Dalgård based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olav Dalgård. Olav Dalgård is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Warnqvist, Anna, et al.. (2024). Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era. International Journal of Drug Policy. 128. 104433–104433. 4 indexed citations

Aass, Hans Christian D., Olav Dalgård, Dan Sun, et al.. (2023). Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines. Scientific Reports. 13(1). 22590–22590.

Finbråten, Ane‐Kristine, et al.. (2023). Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study. International Journal of Drug Policy. 116. 104044–104044. 5 indexed citations

Midgard, Håvard, et al.. (2023). Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial. Clinical Infectious Diseases. 78(3). 582–590. 11 indexed citations

Dalgård, Olav, Alain H. Litwin, Oren Shibolet, et al.. (2022). Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. Journal of Addictive Diseases. 41(3). 213–224. 3 indexed citations

Pawlotsky, Jean–Michel, Francesco Negro, Alessio Aghemo, et al.. (2020). EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology. 73(5). 1170–1218. 707 indexed citations breakdown →

Hajarizadeh, Behzad, Evan B. Cunningham, Heather Valerio, et al.. (2019). Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology. 72(4). 643–657. 114 indexed citations

Wisløff, Torbjørn, Richard White, Olav Dalgård, et al.. (2018). Feasibility of reaching world health organization targets for hepatitis C and the cost‐effectiveness of alternative strategies. Journal of Viral Hepatitis. 25(9). 1066–1077. 6 indexed citations

Hellard, Margaret, Carla Treloar, Julie Bruneau, et al.. (2018). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver International. 39(1). 20–30. 83 indexed citations

10.

Wisløff, Torbjørn, Richard White, Olav Dalgård, et al.. (2018). Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. PharmacoEconomics. 36(5). 591–601. 10 indexed citations

11.

Dalgård, Olav, et al.. (2017). Increased hope following successful treatment for hepatitis C infection. Journal of Advanced Nursing. 74(3). 724–733. 2 indexed citations

12.

Dalgård, Olav, Ola Weiland, Geir Noraberg, et al.. (2017). Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections—A Scandinavian real-life study. PLoS ONE. 12(7). e0179764–e0179764. 23 indexed citations

13.

Midgard, Håvard, Amanda Weir, Norah Palmateer, et al.. (2016). HCV epidemiology in high-risk groups and the risk of reinfection. Journal of Hepatology. 65(1). S33–S45. 125 indexed citations

14.

Lagging, Martin, Mads Rauning Buhl, Peer Brehm Christensen, et al.. (2013). Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scandinavian Journal of Gastroenterology. 48(7). 839–847. 9 indexed citations

15.

Moghaddam, Amir, Espen Melum, Nils Reinton, et al.. (2011). IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Research at the University of Copenhagen (University of Copenhagen). 6 indexed citations

16.

Dalgård, Olav, Amir Moghaddam, Hans Verbaan, et al.. (2010). Il28B Genetic Variation And Treatment Response In Patients With Hcv Genotype 3 Infection. Hepatology. 52(4). 898–898. 4 indexed citations

17.

Björnsson, Einar, Hans Verbaan, Antti Oksanen, et al.. (2009). Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian Journal of Gastroenterology. 44(7). 878–887. 52 indexed citations

18.

Dalgård, Olav, Hans Verbaan, Helmer Ring‐Larsen, & Kristian Bjøro. (2008). IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION AND RVR 14 WEEKS TREATMENT IS NON-INFERIOR TO 24 WEEKS. POOLED ANALYSIS OF TWO SCANDINAVIAN TRIALS. Hepatology. 48(4). 1875–1875. 2 indexed citations

19.

Skaug, Kjell, et al.. (2008). Hepatitt C – et helseproblem også i Norge. Tidsskrift for Den Norske Laegeforening.

20.

Bell, Helge, Olav Dalgård, Kristian Bjøro, Kjell B. Hellum, & Bjørn Myrvang. (2002). Behandling ved kronisk hepatitt C. Tidsskrift for Den Norske Laegeforening. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact